Table 1.
Characteristics of trials included in the systematic review and network meta-analysis
| Trial | Trial characteristic | Country (Centers) | No. of patients | Characteristics of patients | Intervention | Control | Primary outcome | Follow up | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Protocol | Age (% female) | Protocol | Age (% female) | |||||||
| DELIVER 2022 | NCT04418765 | 2 countries (96) | 890 | two-to-four previous treatment failures |
100 mg Eptinezumab; 300 mg Eptinezumab |
44.6 (93%); 43.1 (89%) |
Placebo | 43.8 (88%) | Change in MMDs | 24 weeks |
| LIBERTY 2018 | NCT03096834 | 16 countries (59) | 246 | two-to-four previous treatment failures | 140 mg Erenumab | 44·6 (80%) | Placebo | 44·2 (82%) | 50% response rates | 12 weeks |
| STRIVE 2019 | NCT02456740 | multiple countries (121) | 370 | ≥1 previous treatment failure |
70 mg Erenumab; 140 mg Erenumab |
43.1 (79.5%); 41.4 (92.2%) |
Placebo | 43.9 (84.3%) | Change in MMDs | 24 weeks |
| Hirata 2021 | NCT03812224 | Japan | 117 | ≥1 previous treatment failure | 70 mg Erenumab | 44.8 (91.5%) | Placebo | 44.9 (89.7%) | Change in MMDs | 24 weeks |
| FOCUS 2019 | NCT03308968 | 14 countries (104) | 838 | two-to-four previous treatment failures |
Monthly Fremanezumab; Quarterly Fremanezumab |
45.9 (84%); 45.8 (83%) |
Placebo | 46.8 (84%) | Change in MMDs | 12 weeks |
| Ailani 2020 | NCT02614261 | 12 countries (116) | 98 | onabotulinumtoxinA treatment failure |
120 mg Galcanezumab; 240 mg Galcanezumab |
47.5 (85.7%) | Placebo | 47.5 (85.7%) | Change in MMDs | 12 weeks |
| NCT02614183 | USA (90) | 11 | 46.5 (100%) | Placebo | 46.5 (100%) | Change in MMDs | 24 weeks | |||
| NCT02614196 | 11 countries (109) | 20 | 44.3 (90%) | Placebo | 44.3 (90%) | Change in MMDs | 24 weeks | |||
| CONQUER 2020 | NCT03559257 | 12 countries (64) | 462 | two-to-four previous treatment failures | 120 mg Galcanezumab | 45.9 (84%) | Placebo | 45.7 (88%) | Change in MMDs | 12 weeks |
MMDs Monthly migraine days; USA United States of America